BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28623781)

  • 41. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
    Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
    J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 2-Hydroxyisoquinoline-1,3-Dione Active-Site RNase H Inhibitor Binds in Multiple Modes to HIV-1 Reverse Transcriptase.
    Kirby KA; Myshakina NA; Christen MT; Chen YL; Schmidt HA; Huber AD; Xi Z; Kim S; Rao RK; Kramer ST; Yang Q; Singh K; Parniak MA; Wang Z; Ishima R; Sarafianos SG
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
    Sengupta D; Verma D; Naik PK
    In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
    Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
    Xu Z; Guo J; Yang Y; Zhang M; Ba M; Li Z; Cao Y; He R; Yu M; Zhou H; Li X; Huang X; Guo Y; Guo C
    Eur J Med Chem; 2016 Nov; 123():309-316. PubMed ID: 27484516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Application of Molecular Docking for the Development of Improved HIV-1 Reverse Transcriptase Inhibitors.
    Soltani A; Hashemy SI; Avval FZ; Rafatpanah H; Rezaee SA; Griffith R; Mashkani B
    Curr Comput Aided Drug Des; 2021; 17(4):538-549. PubMed ID: 32598265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase.
    Kodama E; Orita M; Masuda N; Yamomoto O; Fujii M; Ohgami T; Kageyama S; Ohta M; Hatta T; Inoue H; Suzuki H; Sudo K; Shimizu Y; Matsuoka M
    Antivir Chem Chemother; 2008; 19(3):133-41. PubMed ID: 19024630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.
    Frey KM; Gray WT; Spasov KA; Bollini M; Gallardo-Macias R; Jorgensen WL; Anderson KS
    Chem Biol Drug Des; 2014 May; 83(5):541-9. PubMed ID: 24289305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.
    Udier-Blagović M; Tirado-Rives J; Jorgensen WL
    J Med Chem; 2004 Apr; 47(9):2389-92. PubMed ID: 15084137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Schenone S; Bruno O; Bondavalli F; Vargiu L; Marceddu T; Mura M; La Colla P; Pani A
    J Med Chem; 2003 Feb; 46(5):768-81. PubMed ID: 12593657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Clotet B; Esté JA; Cirilli R; Novellino E; Silvestri R
    Eur J Med Chem; 2014 Jun; 80():101-11. PubMed ID: 24769348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
    Gu SX; Li ZM; Ma XD; Yang SQ; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Eur J Med Chem; 2012 Jul; 53():229-34. PubMed ID: 22575532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X.
    Galembeck SE; Bickelhaupt FM; Fonseca Guerra C; Galembeck E
    J Mol Model; 2014 Jul; 20(7):2332. PubMed ID: 24965933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
    Vanangamudi M; Poongavanam V; Namasivayam V
    Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
    Geitmann M; Danielson UH
    Bioorg Med Chem; 2007 Dec; 15(23):7344-54. PubMed ID: 17870544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
    Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
    Li A; Ouyang Y; Wang Z; Cao Y; Liu X; Ran L; Li C; Li L; Zhang L; Qiao K; Xu W; Huang Y; Zhang Z; Tian C; Liu Z; Jiang S; Shao Y; Du Y; Ma L; Wang X; Liu J
    J Med Chem; 2013 May; 56(9):3593-608. PubMed ID: 23540737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
    Udier-Blagović M; Tirado-Rives J; Jorgensen WL
    J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.